Specifically, NUMB has been described as an oncosuppressor in breast cancer (29), esophageal squamous cell carcinoma (27) and mesothelioma (40), but evidence showed also a role for NUMB as an oncogene in hepatocellular carcinoma (41), in astrocytomas (42) in cervical squamous carcinoma cells (43), and in endometrial cancer (44). Here, NUMB is linked to breast cancer.